About Benevir biopharm, inc.
BeneVir Biopharm, Inc. is a biotechnology company that specializes in the development of oncolytic virus therapies for the treatment of cancer. The company was founded in 2011 and is headquartered in Rockville, Maryland.
BeneVir’s mission is to develop innovative therapies that can improve the lives of cancer patients. The company’s focus on oncolytic viruses stems from their unique ability to selectively target and destroy cancer cells while leaving healthy cells unharmed.
One of BeneVir’s most promising technologies is its T-Stealth™ platform, which uses a modified herpes simplex virus (HSV) to deliver therapeutic genes directly into cancer cells. This approach has several advantages over traditional chemotherapy and radiation therapy, including fewer side effects and greater efficacy against metastatic tumors.
In 2018, BeneVir was acquired by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. This acquisition has allowed BeneVir to leverage Janssen’s extensive resources and expertise in immunotherapy research to accelerate the development of its pipeline products.
BeneVir currently has several clinical-stage programs underway, including studies evaluating T-Stealth™ for the treatment of solid tumors such as melanoma and lung cancer. The company also has preclinical programs focused on developing new oncolytic viruses with enhanced potency and specificity.
In addition to its internal R&D efforts, BeneVir collaborates with academic institutions and other industry partners to advance the field of oncolytic virotherapy. These collaborations have resulted in numerous publications in top-tier scientific journals and presentations at major conferences around the world.
Overall, BeneVir Biopharm represents an exciting opportunity for investors looking to capitalize on the growing demand for innovative cancer therapies. With its cutting-edge technology platform and strong partnerships within the industry, this company is well-positioned for success in this rapidly evolving field.